Literature DB >> 33538252

Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs.

Juan M Pericàs1, Jaume Llopis2, Eugene Athan3, Marta Hernández-Meneses1, Margaret M Hannan4, David R Murdoch5, Zeina Kanafani6, Tomas Freiberger7, Jacob Strahilevitz8, Nuria Fernández-Hidalgo9, Cristiane Lamas10, Emanuele Durante-Mangoni11, Pierre Tattevin12, Francisco Nacinovich13, Vivian H Chu14, José M Miró15.   

Abstract

BACKGROUND: Infective endocarditis (IE) in people who inject drugs (PWID) is an emergent public health problem.
OBJECTIVES: The purpose of this study was to investigate IE in PWID and compare it with IE in non-PWID patients.
METHODS: Two prospective cohort studies (ICE-PCS and ICE-Plus databases, encompassing 8,112 IE episodes from 2000 to 2006 and 2008 to 2012, with 64 and 34 sites and 28 and 18 countries, respectively). Outcomes were compared between PWID and non-PWID patients with IE. Logistic regression analyses were performed to investigate risk factors for 6-month mortality and relapses amongst PWID.
RESULTS: A total of 7,616 patients (591 PWID and 7,025 non-PWID) were included. PWID patients were significantly younger (median 37.0 years [interquartile range: 29.5 to 44.2 years] vs. 63.3 years [interquartile range: 49.3 to 74.0 years]; p < 0.001), male (72.5% vs. 67.4%; p = 0.007), and presented lower rates of comorbidities except for human immunodeficiency virus, liver disease, and higher rates of prior IE. Amongst IE cases in PWID, 313 (53%) episodes involved left-side valves and 204 (34.5%) were purely left-sided IE. PWID presented a larger proportion of native IE (90.2% vs. 64.4%; p < 0.001), whereas prosthetic-IE and cardiovascular implantable electronic device-IE were more frequent in non-PWID (9.3% vs. 27.0% and 0.5% vs. 8.6%; both p < 0.001). Staphylococcus aureus caused 65.9% and 26.8% of cases in PWID and non-PWID, respectively (p < 0.001). PWID presented higher rates of systemic emboli (51.1% vs. 22.5%; p < 0.001) and persistent bacteremia (14.7% vs. 9.3%; p < 0.001). Cardiac surgery was less frequently performed (39.5% vs. 47.8%; p < 0.001), and in-hospital and 6-month mortality were lower in PWID (10.8% vs. 18.2% and 14.4% vs. 22.2%; both p < 0.001), whereas relapses were more frequent in PWID (9.5% vs. 2.8%; p < 0.001). Prior IE, left-sided IE, polymicrobial etiology, intracardiac complications, and stroke were risk factors for 6-month mortality, whereas cardiac surgery was associated with lower mortality in the PWID population.
CONCLUSIONS: A notable proportion of cases in PWID involve left-sided valves, prosthetic valves, or are caused by microorganisms other than S. aureus.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV; Staphylococcus aureus; cardiac surgery; infective endocarditis; opioid crisis; people who inject drugs

Year:  2021        PMID: 33538252     DOI: 10.1016/j.jacc.2020.11.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

Review 1.  Staphylococcus Aureus Infective Endocarditis: JACC Patient Pathways.

Authors:  Julia Grapsa; Christopher Blauth; Y S Chandrashekhar; Bernard Prendergast; Blair Erb; Michael Mack; Valentin Fuster
Journal:  JACC Case Rep       Date:  2021-11-15

2.  Epidemiologic and clinical characteristics of infective endocarditis: a single-center retrospective study in the Bronx, New York.

Authors:  Wasla Liaqat; Leonidas Palaiodimos; Weijia Li; Dimitrios Karamanis; Arooj Tahir; Andreas Tzoumas; Sanjana Nagraj; Nidhish Tiwari; Michael Grushko; Damianos Kokkinidis; Eleonora Gashi; Jason Leider; Christina Coyle; Robert T Faillace
Journal:  Infection       Date:  2022-05-25       Impact factor: 7.455

3.  Steep rise in drug use-associated infective endocarditis in West Virginia: Characteristics and healthcare utilization.

Authors:  Ruchi Bhandari; Talia Alexander; Frank H Annie; Umar Kaleem; Affan Irfan; Sudarshan Balla; R Constance Wiener; Chris Cook; Aravinda Nanjundappa; Mark Bates; Ellen Thompson; Gordon S Smith; Judith Feinberg; Melanie A Fisher
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

4.  Correlates of 90-Day Mortality Among People Who Do and Do Not Inject Drugs With Infective Endocarditis in Seattle, Washington.

Authors:  Maria A Corcorran; Jenell Stewart; Kristine Lan; Ayushi Gupta; Sara N Glick; Chetan Seshadri; Kevin J Koomalsingh; Edward F Gibbons; Robert D Harrington; Shireesha Dhanireddy; H Nina Kim
Journal:  Open Forum Infect Dis       Date:  2022-03-29       Impact factor: 4.423

5.  The Epidemiology of Endocarditis in Manitoba: A Retrospective Study.

Authors:  Duncan J Maguire; Rakesh C Arora; Brett M Hiebert; Brenden Dufault; Mullein D Thorleifson
Journal:  CJC Open       Date:  2021-07-29

6.  Temporal trends and patterns of infective endocarditis in a Chinese population: A territory-wide study in Hong Kong (2002-2019).

Authors:  Hang-Long Li; Jasper Tromp; Kanako Teramoto; Yi-Kei Tse; Si-Yeung Yu; Lok-Yee Lam; Kwan-Yu Li; Mei-Zhen Wu; Qing-Wen Ren; Pui-Fai Wong; Ching-Lung Cheung; Kelvin Kai-Wang To; Hung-Fat Tse; Carolyn S P Lam; Kai-Hang Yiu
Journal:  Lancet Reg Health West Pac       Date:  2022-03-04

7.  Different drugs, different sides: injection use of opioids alone, and not stimulants alone, predisposes to right-sided endocarditis.

Authors:  Rochelle Johnstone; Nadine Khalil; Esfandiar Shojaei; Klajdi Puka; Lise Bondy; Sharon Koivu; Michael Silverman
Journal:  Open Heart       Date:  2022-07

8.  Evolving mortality rates in people who inject drugs: An Australian tertiary hospital observational study on infective endocarditis.

Authors:  Isa Khan; Elizabeth Brookes; John Santamaria; Daniel Crisafi; Andrew Wilson; Jonathan Darby; Andrew Newcomb
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

9.  Percutaneous Aspiration of Vegetation in Tricuspid Valve Infective Endocarditis: A Possible Novel Treatment Option.

Authors:  Abdelkader Almanfi; Ibrahim Nabous
Journal:  JACC Case Rep       Date:  2022-09-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.